Fig. 1: A large-scale drug combination screen.
From: Effective drug combinations in breast, colon and pancreatic cancer cells
a, 2,025 drug combinations were screened in breast, colon and pancreas cancer cell lines (n = 125). Synergy was evaluated on the basis of efficacy (ΔEmax) and potency (ΔIC50) for 108,259 drug responses and integrated with cell line molecular features to identify biomarkers. b, Heat map of ΔIC50 values for 1,275 combinations in 51 breast cancer cell lines: clustering by combination and annotation by combination type, anchor and library pathway. ΔIC50 limits are clipped to −4 and 4, rows are sorted by conditional mean ΔIC50 on cell line identity. Chemo., chemotherapeutic agent.
